Boehringer, Ventana to collaborate on oncology tests

Boehringer Ingelheim has entered into an oncology companion diagnostic test development collaboration with Ventana Medical Systems, Inc., which is a member of the Roche Group.

Under terms of the agreement, Ventana will utilize its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim’s personalised medicine healthcare strategies for cancer drug development.

“We are pleased that Ventana’s commitment to enable Personalized Healthcare for patients worldwide was recognized by Boehringer Ingelheim when they selected Ventana to be a companion diagnostics development partner for their oncology programmes.”

Mara G. Aspinall, President, Ventana Medical Systems, Inc.

Companion diagnostic tests provide information that can help physicians to choose targeted treatments for their patients based on the expected best response to therapy.

“We look forward to partnering with Ventana and accessing their significant capabilities and expertise in developing companion diagnostics that will complement our products to further advance the delivery of personalized healthcare solutions for patients.”

Klaus Dugi, Corporate Senior Vice President, Medicine at Boehringer Ingelheim.

 

Related news:

Boehringer Ingelheim and Ventana to ally on oncology tests (Zenopa)

Reference links:

Boehringer Ingelheim press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.